The Hohn catheter in the management of haemopoietic stem cell transplant recipients.
Patients undergoing bone marrow transplantation require a reliable venous access. The authors have tested the feasibility and safety of a new, silicone, open-ended, non-tunnelled central venous catheter (CVC), the Hohn catheter (Bard Access System, USA). From January 1994 to December 1996, 58 Hohn were inserted into 56 bone marrow transplant (BMT) patients (26 women: 30 men; mean age 38 years, range 19-62 years). The CVC was inserted percutaneously at the bedside by puncture of the subclavian or the internal jugular vein. No early complications were observed. Significant late complications were infection (documented only in 14%) and accidental removal (11%). The median life of the CVC was 30 days (range 15-180 days). Major causes of removal were end of use (25 patients) and fever (19 patients; but infection was documented only in eight patients). In spite of the relatively small gauge (5 Fr), the Hohn catheter was adequate for rapid or high density infusion. In our experience, the unique features of the Hohn CVC (versatility, optimal biocompatibility, bedside management, low cost) may contribute to making the BMT procedure safer and less expensive.
Salutari
P
P
Department of Haematology, Catholic University, Rome, Italy.
Pittiruti
M
M
Sica
S
S
Agresti
M
M
Chiusolo
P
P
Leone
G
G
D000328:Adult; D016026:Bone Marrow Transplantation / Q000295:instrumentation*; D002405:Catheterization, Central Venous / Q000295:instrumentation*; D002408:Catheters, Indwelling / Q000009:adverse effects; D004868:Equipment Failure; D005240:Feasibility Studies; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000295:instrumentation*; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008422:Materials Testing; D008875:Middle Aged